Japanese company profile · 9987

SUZUKEN CO.,LTD.

English company name recorded in Japan's EDINET filer data.

Original Japanese company name: 株式会社スズケン

Name follows the English name recorded in EDINET filer data. English company name source

FY2025 · fiscal year ended March 2026Latest filing date: 2026-06-22

What does this company do?

What does this company do?

In its FY2025 public filing, SUZUKEN CO.,LTD. reports Pharmaceutical Wholesale Business, Healthcare product development, Regional health care support scheme, Specialty Pharmaceutical Distribution Trust, and 1 other reported businesses. The page shows business-level revenue and profit where the source disclosures support comparison.

SUZUKEN CO.,LTD.'s largest reported business by revenue in FY2025 was Pharmaceutical Wholesale Business.

The business with the highest reported segment profit in FY2025 was Pharmaceutical Wholesale Business.

FY2025 · fiscal year ended March 2026 · View original filing ↗ The source document may be in Japanese.

Reported company-wide figures

Company revenue
¥2.49T ↗
FY2025 · fiscal year ended March 2026
Operating profit
¥36.37B ↗
FY2025 · fiscal year ended March 2026
Comparable margin
1.5% ↗
FY2025 · fiscal year ended March 2026

JGAAP · Consolidated company-wide

Company profile

Company profile

Identity

Securities code
9987
EDINET code
E02780
Corporate number
1180001017009
Listing status
Listed
Industry (EDINET filer classification)
Wholesale trade

Location and fiscal year

Headquarters
名古屋市東区 · As filed in Japanese
Fiscal year end
3month
Latest fiscal year
FY2025
Accounting standard
JGAAP
P16 data snapshot
2026-11-07

Company size

Employees (consolidated)
12,717 people (FY2025)
Employees (non-consolidated)
2,991 people (FY2025)
Capital stock
JPY 13.5 billion (FY2025)

Official information

Public information is organized and presented by P16. EDINET filer list (2026-11-07) Opens in a new tab · EDINET PDL 1.0 terms Opens in a new tab

Business structure

How does it make money?

Revenue leader and profit leader

Pharmaceutical Wholesale Business

FY2025 · fiscal year ended March 2026 · Business Sales Operating profit
BusinessSalesShare of company salesOperating profitMargin
Pharmaceutical Wholesale Business¥2.4T ↗—¥31.47B ↗1.3%
Specialty Pharmaceutical Distribution Trust¥436.1B ↗—¥1.16B ↗0.3%
Regional health care support scheme¥93.94B ↗—¥1.55B ↗1.6%
Healthcare product development¥51.64B ↗—¥830M ↗1.6%
Healthcare related services¥42.96B ↗—¥1.28B ↗3.0%

All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison. “—” means a comparable amount was not disclosed. We compare sales to outside customers for each business and the company as a whole, using the same filing, fiscal year and scope. Reported business sales may include sales between businesses. We leave the share blank when the figures cannot be matched.

Company revenue

Company-wide trend

Company revenue

JGAAP · Consolidated
  1. FY202189.8¥2.23T
  2. FY202293.1¥2.31T
  3. FY202396.0¥2.39T
  4. FY202496.5¥2.4T
  5. FY2025100.0¥2.49T

Company operating profit

JGAAP · Consolidated
  1. FY202137.1¥13.78B
  2. FY202287.8¥32.6B
  3. FY202393.9¥34.88B
  4. FY2024100.0¥37.12B
  5. FY202598.0¥36.37B

Only reported years are shown. Missing years are left blank; accounting standards and scopes are kept in separate series.

What has changed?

Businesses reported in earlier filings

Reporting labels alone do not prove that a business started, ended, merged, or changed its identity.

  • 医薬品製造事業 (Original Japanese label)FY 2021–FY 2022 · Source
  • Insurance pharmacy businessFY 2021–FY 2022 · Source

What is growing?

What is growing?

Business revenue growth

This describes a reported period; it is not a forecast.

What has changed?

What has changed?

A five-year business-mix comparison is not shown because the available filings do not provide five comparable years on the same basis.

Source

Company profile

These scores summarize company characteristics using public filings. Comparison groups vary by measure. Higher is not always better.

  • Growth26
    Peer-position scoreFY2025
  • Profitability16
    Peer-position scoreFY2025
  • Business concentration—
    No comparable data
  • Business change—
    No comparable data
  • Cash generation25
    Peer-position scoreFY2025
  • Growth persistence79
    Peer-position scoreFY2021→FY2022, FY2022→FY2023, FY2023→FY2024, FY2024→FY2025

Next

Ask about this company

Source

Public filing

FY2025 · fiscal year ended March 2026

The source document may be in Japanese.

Filing ID: S100YFRU

View original filing ↗
Original Japanese label
Original Japanese label
医薬品製造事業

根拠となる資料